Search hospitals
>
Nova Scotia
>
HALIFAX
Queen Elizabeth II Health Sciences Centre
Claim this profile
HALIFAX, Nova Scotia B3H 2Y9
Global Leader in Breast Cancer
Global Leader in Multiple Myeloma
Conducts research for Prostate Cancer
Conducts research for Cancer
Conducts research for Crohn's Disease
372 reported clinical trials
31 medical researchers
Summary
Queen Elizabeth II Health Sciences Centre is a medical facility located in HALIFAX, Nova Scotia. This center is recognized for care of Breast Cancer, Multiple Myeloma, Prostate Cancer, Cancer, Crohn's Disease and other specialties. Queen Elizabeth II Health Sciences Centre is involved with conducting 372 clinical trials across 387 conditions. There are 31 research doctors associated with this hospital, such as David P. Lee, MD, Ivan Wong, MD, Ricardo Rendon, MD, and Sudeep Shivakumar, MD.
Area of expertise
Breast Cancer
Queen Elizabeth II Health Sciences Centre has run 22 trials for Breast Cancer. Some of their research focus areas include:
Multiple Myeloma
Queen Elizabeth II Health Sciences Centre has run 22 trials for Multiple Myeloma. Some of their research focus areas include:
Top PIs
David P. Lee, MD
Stanford Hospital and Clinics
8 years of reported clinical research
Ivan Wong, MD
Nova Scotia Health Authority
5 years of reported clinical research
Ricardo Rendon, MD
Queen Elizabeth II Health Sciences Centre
5 years of reported clinical research
Sudeep Shivakumar, MD
Queen Elizabeth II Health Sciences Centre
8 years of reported clinical research
Clinical Trials running at Queen Elizabeth II Health Sciences Centre
Acute Myeloid Leukemia
Multiple Myeloma
Chronic Lymphocytic Leukemia
Idiopathic Pulmonary Fibrosis
Acute Myelogenous Leukemia
Cardiovascular Disease
Breast Cancer
Atrial Fibrillation
Pancreatic Cancer
Sarcoidosis
Bleximenib + Venetoclax + Azacitidine
for Acute Myeloid Leukemia
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
Recruiting
1 award
Phase 3
3 criteria
Combination Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.
Recruiting
1 award
Phase 2
6 criteria
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting
1 award
Phase 2
17 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Queen Elizabeth II Health Sciences Centre?
Queen Elizabeth II Health Sciences Centre is a medical facility located in HALIFAX, Nova Scotia. This center is recognized for care of Breast Cancer, Multiple Myeloma, Prostate Cancer, Cancer, Crohn's Disease and other specialties. Queen Elizabeth II Health Sciences Centre is involved with conducting 372 clinical trials across 387 conditions. There are 31 research doctors associated with this hospital, such as David P. Lee, MD, Ivan Wong, MD, Ricardo Rendon, MD, and Sudeep Shivakumar, MD.
Where is Queen Elizabeth II Health Sciences Centre located?
The Queen Elizabeth II Health Sciences Centre, situated in downtown Halifax, Nova Scotia, Canada, encompasses two main campuses: the Victoria site and the Halifax Infirmary site. The Victoria site houses the Nova Scotia Rehabilitation Centre, Bethune, Mackenzie, Centre for Clinical Research, Dickson, Victoria, and Centennial buildings. Meanwhile, the Halifax Infirmary site is comprised of the Halifax Infirmary, Charles V. Keating Emergency and Trauma Centre, Abbie J. Lane Memorial, and Camp Hill Veteran's Memorial buildings, with the emergency department located at the south end of the Halifax Infirmary site.
Who should I call to ask about financial aid or insurance network?
The Queen Elizabeth II Health Sciences Centre offers the QEII Patient Assistance Fund, granting up to $1000 to eligible patients for expenses such as rent, mortgage, lodging, home utilities, and other medical-related costs. For detailed information on financial assistance and insurance, contact the hospital directly at their main switchboard (902-473-2700) or patient switchboard (902-473-1510). Further details on the hospital's financial assistance policy and application process are available on The Queen's Health System website.
What insurance does Queen Elizabeth II Health Sciences Centre accept?
The Queen Elizabeth II Health Sciences Centre in Nova Scotia, Canada, is a leading multi-campus teaching and research organization. It offers specialized medical treatments, innovative therapies, and is affiliated with the Dalhousie University Faculty of Medicine. Patients should contact their insurance company for current coverage information at the Queen Elizabeth II Health Sciences Centre.
What awards or recognition has Queen Elizabeth II Health Sciences Centre received?
The Queen Elizabeth II Health Sciences Centre Foundation, located in Halifax, Nova Scotia, reported total revenues of $13.4 million in F2021, thanks to various campaigns and donations. It manages its investments through external investment managers, incurring fees based on market value. With funding reserves of $96 million, the Foundation can sustain its F2021 grant level for nearly eleven years.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.